SecurityCP / Canadian Pacific Railway Ltd. (13645T100)
IndustryRailroads, Line-Haul Operating
Common Stock Shares Outstanding146,100,000 shares (as of 2017-06-30)
Total Insiders27
Total Directors13
Total Officers14

Stock Insider Trading (from SEC Form 4)

Canadian Pacific Railway Ltd. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CP / Canadian Pacific Railway Ltd. insiders include Johnson Robert Allen, Harrison E Hunter, TRAFTON GORDON T. II Pershing Square Capital Management, L.P., PS Management GP, LLC, Pitz Laird Joseph, MacDonald Ubavka Rebecca, Foran Mike, Velani Nadeem, ACKMAN WILLIAM A, Brooks John Kenneth, and Derry John E, Clements James Dominic Luther, Fatt William R., Edwards Peter John, Creel Keith Edward, Ellis Jeffrey Jerom, PAULL MATTHEW H, Erceg Mark J, Reardon Andrew Fitzpatrick, Wallace Mark Kenneth, Courville Isabelle, Peverett Jane L, Redeker Michael John, DENHAM GILLIAN H, Melman Anthony Ronald, Baird John Russell, .

Insider Roster

Insider Dir Off 10% Shares Owned
MacDonald Ubavka Rebecca Director
X
Baird John Russell Director
X
Reardon Andrew Fitzpatrick Director
X
Courville Isabelle Director
X
TRAFTON GORDON T. II Director
X
Fatt William R. Director
X
DENHAM GILLIAN H Director
X
Peverett Jane L Director
X
PAULL MATTHEW H Director
X
Brooks John Kenneth SVP & Chief Marketing Officer
X 1,587
Clements James Dominic Luther VP Planning & Transportation
X 1,921
Derry John E Vice-President Human Resources
X 242
Ellis Jeffrey Jerom Chief Legal Officer & Corp Sec
X 299
Johnson Robert Allen Executive VP Operations
X 97
Foran Mike VP Network Transportation
X 1,591
Creel Keith Edward President & CEO, Director
X X 2,087
Velani Nadeem VP and CFO
X 340
Redeker Michael John VP & Chief Information Officer
X 951
Edwards Peter John VP People
X 2,456
Pitz Laird Joseph VP & Chief Risk Officer
X
Wallace Mark Kenneth VP Corp Affrs & Chief of Staff
X
Harrison E Hunter Chief Executive Officer, Director
X X
Pershing Square Capital Management, L.P.
ACKMAN WILLIAM A
PS Management GP, LLC
Erceg Mark J EVP & CFO
X
ACKMAN WILLIAM A Director
Pershing Square Capital Management, L.P. Director
PS Management GP, LLC Director
X
Melman Anthony Ronald Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2017-06-30 4 Redeker Michael John By ESPP J I 162.18 15 951
2017-06-30 4 Velani Nadeem By ESPP J I 162.18 13 340
2017-06-30 4 Creel Keith Edward By ESPP J I 159.63 47 2,087
2017-06-30 4 Foran Mike By ESPP J I 162.18 7 1,591
2017-06-30 4 Johnson Robert Allen By ESPP J I 159.63 27 97
2017-06-30 4 Ellis Jeffrey Jerom By ESPP J I 162.16 13 299
2017-06-30 4 Derry John E By ESPP J I 162.16 10 242
2017-06-30 4 Clements James Dominic Luther By ESPP J I 162.12 10 1,921
2017-06-30 4 Brooks John Kenneth By ESPP J I 159.63 15 1,587
2017-05-31 4 Redeker Michael John By ESPP J I 158.86 15 936
2017-05-31 4 Foran Mike By ESPP J I 158.86 8 1,584
2017-05-31 4 Velani Nadeem By ESPP J I 158.88 13 327
2017-05-31 4 Derry John E By ESPP J I 158.81 9 232
2017-05-31 4 Clements James Dominic Luther By ESPP J I 158.90 10 1,911
2017-05-31 4 Ellis Jeffrey Jerom By ESPP J I 158.83 13 286
2017-06-01 4 Brooks John Kenneth By ESPP J I 159.79 14 1,572
2017-06-01 4 Creel Keith Edward By ESPP J I 159.79 46 2,040
2017-06-01 4 Johnson Robert Allen By ESPP J I 159.79 28 70
2017-05-02 4 Redeker Michael John By ESPP J I 153.18 17 921
2017-05-02 4 Velani Nadeem By ESPP J I 153.16 14 314
2017-05-02 4 Foran Mike By ESPP J I 153.22 19 1,576
2017-05-02 4 Johnson Robert Allen By ESPP J I 154.67 28 42
2017-05-02 4 Edwards Peter John By ESPP J I 153.27 23 2,456
2017-05-02 4 Ellis Jeffrey Jerom By ESPP J I 153.24 14 273
2017-05-02 4 Clements James Dominic Luther By ESPP J I 153.31 14 1,901
2017-05-02 4 Creel Keith Edward By ESPP J I 154.72 45 1,994
2017-04-28 4 Creel Keith Edward By ESPP J I 154.63 3 1,949
2017-05-02 4 Derry John E By ESPP J I 153.25 10 223
2017-05-02 4 Brooks John Kenneth By ESPP J I 154.72 15 1,558
2017-04-28 4 Brooks John Kenneth By ESPP J I 154.63 3 1,543
2017-03-31 4 Redeker Michael John By ESPP J I 147.98 17 904
2017-03-31 4 Foran Mike By ESPP J I 148.02 7 1,557
2017-03-31 4 Brooks John Kenneth By ESPP J I 146.39 14 1,540
2017-03-31 4 Creel Keith Edward By ESPP J I 146.39 44 1,946
2017-03-31 4 Derry John E By ESPP J I 148.06 10 213
2017-03-31 4 Johnson Robert Allen By ESPP J I 146.39 14 14
2017-03-31 4 Edwards Peter John By ESPP J I 148.06 19 2,433
2017-03-31 4 Clements James Dominic Luther By ESPP J I 148.06 11 1,887
2017-03-31 4 Velani Nadeem By ESPP J I 148.02 15 300
2017-03-31 4 Ellis Jeffrey Jerom By ESPP J I 148.08 14 259
2017-03-21 4 Edwards Peter John F D 146.79 -4,503 6,830
2017-03-21 4 Edwards Peter John M D 37.28 10,300 11,333
2017-03-01 4 Clements James Dominic Luther By ESPP J I 146.37 11 1,876
2017-03-01 4 Velani Nadeem By ESPP J I 146.52 13 285
2017-03-01 4 Redeker Michael John By ESPP J I 146.50 16 887
2017-03-01 4 Creel Keith Edward By ESPP J I 149.53 42 1,902
2017-03-01 4 Derry John E By ESPP J I 146.39 10 203
2017-03-01 4 Edwards Peter John By ESPP J I 146.49 18 2,414
2017-03-01 4 Ellis Jeffrey Jerom By ESPP J I 146.49 14 245
2017-03-01 4 Brooks John Kenneth By ESPP J I 149.53 12 1,526
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

CP Rail wants to put digital signs on its bridges in downtown Calgary

2018-07-17 cbc.ca
Canadian Pacific Railway would like to get more bang for its buck when it comes to advertising on its bridges in downtown Calgary.

From casinos to cannabis: how a tiny First Nation forged a big business empire

2018-07-16 cbc.ca
It's a blistering July afternoon at the Edmundston Truck Stop. The air vibrates with the low rumbling of a dozen idling 18-wheelers burning fuel. (4-0)

More than $50,000 raised to bring NSW man home after horror train accident in Canada

2018-07-13 smh.com.au
More than $50,000 has been raised to help a Hunter man come home after he lost limbs in a train accident in Canada.

City launches 3 projects to spruce up Downtown West section of Calgary's core

2018-07-11 cbc.ca
The City of Calgary is trying to spruce up the appearance of the western end of downtown by helping business owners revitalize their facades, setting aside spaces for art murals and creating temporary parks.

Will High Costs Hamper Canadian Pacific's (CP) Q2 Earnings?

2018-07-11 zacks
Canadian Pacific Railway Limited (CP - Free Report) is scheduled to report second-quarter 2018 results on Jul 18 after market close. Last reported quarter, the company came up with a negative earnings surprise of 1.4% on lower-than-expected earnings and revenues. Results were hurt by rough weather conditions. However, the top and the bottom line improved from the year-ago figures. Things do not look up for the company this to-be-reported quarter too. (1-0)